Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

Carcinoma, Non-Small Cell Lung Clinical Trial

Official title:

Efficacy and Safety of Bronchial Arterial Infusion Chemotherapy Combined With Drug Loaded Microspheres Embolization With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05380271
• Other study ID #: IAT-NSCLC-2022-04
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 1, 2022
• Est. completion date: December 1, 2025

Study information

• Verified date: May 2022
• Source: The First Affiliated Hospital of Zhengzhou University
• Contact: Gang Wu, M.D.
• Phone: +86 13938570175
• Email: wuganghenan2015[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open-labelled study to evaluate the efficacy and safety of arterial infusion chemotherapy combined with drug loaded microspheres embolization with sequential arotinib and tirelizumab in the treatment of advanced NSCLC. The progression-free-survival (PFS) will be evaluated as the primary endpoints.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: December 1, 2025
• Est. primary completion date: December 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Has fully understood and voluntarily signed an written Informed Consent and agreed to follow the research plan treatment and visiting plan;

2. Aged >=18 years, <= 85 years;

3. Patients with NSCLC diagnosed by imaging and histopathology; TNM stage was III-IV;

4. Initial diagnosis, failure of first-line treatment, refusal or inability to perform routine treatment (surgery, radiotherapy and chemotherapy);

5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

6. Expected survival period = 3 months.

Exclusion Criteria:

1. Known hypersensitivity to any of the study drugs or excipients;

2. Hypertension that is not controlled by the drug;

3. International normalized ratio (INR) > 1.5 or partially activated prothrombin time (APTT) > 1.5 × ULN;

4. WBC count < 3000 /mm3;

5. Platlet count < 50000 /mm3;

6. Poorly controlled diabetes before enrollment;

7. Clinically significant electrolyte abnormalities judged by researchers;

8. Patients with obvious evidence of bleeding tendency or medical history of hematochezia within 3 months before enrollment;

9. Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe / unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment; Congestive heart failure, New York Heart Association (NYHA) grade > 2; ventricular arrhythmia requiring drug treatment; LVEF (left ventricular ejection fraction) < 50%;

10. Active infection or serious infection that is not controlled by drug;

11. History of clinically significant hepatic disease (ALT and/or AST >5 times the upper normal limit);

12. Women who are pregnant or lactating;

13. Urinary protein = ++, and the 24-hour urine protein quantification is greater than 1.0g;

14. Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions, which according to the judgment of the investigator, it is reasonable to suspect that the patient is not suitable for the use of the study drug.

Related Conditions & MeSH terms

• Carcinoma, Non-Small Cell Lung
• Carcinoma, Non-Small-Cell Lung

Intervention

Drug:
• sequential DEB-BACE and Arotinib and Tirelizumab
DEB-BACE+Arotinib + Tirelizumab
• DEB-BACE alone
DEB-BACE alone

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Gang Wu

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	PFS was defined as the time from recruitment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.	up to 3 years
Secondary	ORR	ORR is defined as the percentages of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria	up to 3 years
Secondary	Overall survival (OS)	The time from recruitment to death due to any cause.	up to 3 years